Loss of heterozygosity in human skin

Journal of the American Academy of Dermatology

Volumn 41, Issue 2 I, 1999, Pages 143-161

  Happle, R ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARCINOGENESIS; GENETIC LINKAGE; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; MALIGNANT TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; SKIN CANCER; SKIN DISEASE;

EID: 0032777704     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(99)70042-3     Document Type: Article

References (265)

1. Zhu X, Dunn JM, Goddard AD, Squire JA, Becker A, Philipps RA, et al. Mechanisms of loss of heterozygosity in retinoblastoma. Cytogenet Cell Genet 1992;59:248-52.
2. Shannon KM, O’Connell P, Martin GA, Paderanga D, Olson K, Dinndorf P, et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med 1994;330:597-601.
3. Menon AG, Anderson KM, Riccardi VM, Chung RY, Whaley JM, Yandell DW, et al. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc Natl Acad Sci U S A 1990;87:5435-9.
4. Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer.New York:McGraw-Hill; 1988.
5. German J. Cytological evidence for crossing-over in vitro in human lymphoid cells. Science 1964;144:298-301.
6. German J. Genetic disorders associated with chromosomal instability and cancer. J Invest Dermatol 1973;60:427-34.
7. Cavenee WK, Dryja TP, Phillips RA, Benedict WF, Godbout R, Gallie BL, et al. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 1983;305:779-84.
8. Hall JG. Somatic mosaicism: observations related to clinical genetics. Am J Hum Genet 1988;43:355-63.
9. Groden J, Nakamura Y, German J. Molecular evidence that homologous recombination occurs in proliferating human somatic cells. Proc Natl Acad Sci U S A 1990;87:4315-9.
10. White VA, McNeil BK, Horsman DE. Acquired homozygosity (isodisomy) of chromosome 3 in uveal melanoma. Cancer Genet Cytogenet 1998;102:40-5.
11. Aviv A, Aviv H. Telomeres, hidden mosaicism, loss of heterozygosity, and complex genetic traits. Hum Genet 1998; 103:2-4.
12. Martens UM, Zijlmans JM, Poon SS, Dragowska W, Yui J, Chavez EA, et al. Short telomeres on human chromosome 17p.Nature Genet 1998;18:76-80.
13. Happle R. Mosaicism in human skin: understanding the patterns and mechanisms. Arch Dermatol 1993;129:1460-70.
14. Patterson JT. The production of mutations in somatic cells of Drosophila melanogaster by means of X-rays. J Exp Zool 1929;53:327-72.
15. Stern C. Somatic crossing over and segregation in Drosophila melanogaster.Genetics 1936;21:625-730.
16. Comings DE. A general theory of carcinogenesis. Proc Natl Acad Sci U S A 1973;70:3324-8.
17. Armitage P, Doll R. A two stage theory of carcinogenesis in relation to the age distribution of human cancer. Br J Cancer 1957;11:161-9.
18. Knudson AG Jr. Mutation and cancer: a statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971;68:820-3.
19. Knudson AG, Hethcote HW, Brown BW. Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. Proc Natl Acad Sci U S A 1975;72:5116-20.
20. Hethcote HW, Knudson AG.Model for the incidence of embryonal cancers: application to retinoblastoma.Proc Natl Acad Sci U S A 1978;75:2453-7.
21. Jackson CE, Block MA, Greenwald KA, Tashijan AH Jr. The twomutational- event theory in medullary thyroid cancer. Am J Hum Genet 1979;31:704-10.
22. Langlois RG, Bigbee WL, Jensen RH, German J. Evidence for increased in vivo mutation and somatic recombination in Bloom’s syndrome. Proc Natl Acad Sci U S A 1989;86:670-4.
23. Caron H, van Sluis P, Buschman R, Pereira do Tanque R, Maes P, Beks L, et al. Allelic loss of the short arm of chromosome 4 in neuroblastoma suggests a novel tumour suppressor gene locus. Hum Genet 1996;97:834-7.
24. Gailani MR, Bale SJ, Leffell DJ, DiGiovanna JJ, Peck GL, Poliak S, et al. Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. Cell 1992;69:111-7.
25. Chevenix-Trench G, Wicking C, Berkman J, Sharpe H, Hockey A, Haan E, et al. Further localization of the gene for nevoid basal cell carcinoma syndrome (NBCCS) in 15 Australian families: linkage and loss of heterozygosity. Am J Hum Genet 1993;7:760-7.
26. Quinn AG, Campbell C, Healy E, Rees JL. Chromosome 9 allele loss occurs in both basal and squamous cell carcinomas of the skin. J Invest Dermatol 1994;102:300-3.
27. Holmberg E, Rozell BL, Toftgård R. Differential allele loss on chromosome 9q22.3 in human non-melanoma skin cancer. Br J Cancer 1996;74:246-50.
28. Ahmadian A, Ren ZP, Williams C, Ponten F, Odeberg J, Ponten J, et al. Genetic instability in the 9q22.3 region is a late event in the development of squamous cell carcinoma. Oncogene 1998;17:1837-43.
29. Goudie DR, Yuille MA, Leversha MA, Furlong RA, Carter NP, Lush MJ, et al. Multiple self-healing squamous epitheliomata (ESS1) mapped to chromosome 9q22-q31 in families with common ancestry. Nature Genet 1993;3:165-9.
30. Richards FM, Goudie DR, Cooper WN, Jene Q, Barroso I, Wicking C, et al. Mapping the multiple self-healing squamous epithelioma (MSSE) gene and investigation of xeroderma pigmentosum group A (XPA) and PATCHED (PTCH) as candidate genes. Hum Genet 1997;101:317-22.
31. Healy E, Rehman I, Angus B, Rees JL. Loss of heterozygosity in sporadic primary cutaneous melanoma. Genes Chromosom Cancer 1995;12:152-6.
32. Volkenandt M, Schlegel U, Nanus DM, Albino AP. Mutational analysis of the human p53 gene in malignant melanoma cell lines. Pigment Cell Res 1991;4:35-40.
33. Fountain JW, Karayiorgou M, Ernstoff MS, Kirkwood JM, Vlock DR, Titus-Ernstoff L, et al. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci U S A 1992;89:10557-61.
34. Funk JO, Schiller PI, Barrett MT, Wong DJ, Kind P, Sander CA. p16INK4a expression is frequently decreased and associated with 9p21 loss of heterozygosity in sporadic melanoma. J Cutan Pathol 1998;25:291-6.
35. Healy E, Belgaid C, Takata M, Harrison D, Zhu NW, Burd DA, et al. Prognostic significance of allelic losses in primary melanoma. Oncogene 1998;16:2213-8.
36. Ruiz A, Puig S, Lynch M, Castel T, Estivill X. Retention of the CDKN2A locus and low frequency of point mutations in primary and metastatic cutaneous malignant melanoma. Int J Cancer 1998;76:312-6.
37. Quezado MM, Abati AD, Albuquerque AV, Wilson J, Merino MJ, Filie AC. Morphologic diversity in malignant melanoma: the potential use of microdissection and the polymerase chain reaction for diagnosis.Mod Pathol 1998;11:1010-5.
38. Tsao H, Zhang X, Benoit E, Halusaka FG. Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene 1998;16:3397-402.
39. Robertson GP, Furnari FB, Miele ME, Glendening MJ, Welch DR, Fountain JW, et al. In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. Proc Natl Acad Sci U S A 1998;95:9418-23.
40. Reifenberger J, Wolter M, Boström J, Schulte KW, Megahed M, Ruzicka T, et al. Allelic losses on chromosome arm 10q and mutation of the PTEN tumor suppressor gene in primary and metastatic malignant melanomas [abstract]. Arch Dermatol Res 1999;403:124.
41. Kamb A, Herlyn M. Malignant melanoma. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. New York:McGraw-Hill; 1998. p. 507-18.
42. Talwalkar VR, Scheiner M, Hedges LK, Butler MG, Schwartz HS. Microsatellite instability in malignant melanoma. Cancer Genet Cytogenet 1998;104:111-4.
43. Morita R, Fuijmoto A, Hatta N, Takehara K, Takata M. Comparison of genetic profiles between primary melanomas and their metastases reveals genetic alterations and clonal evolution during progression. J Invest Dermatol 1998;111: 919-24.
44. Van Gele M, Van Roy N, Ronan SG, Messian L, Vandesompele J, Geerts ML et al. Molecular analysis of 1p36 breakpoints in two Merkel cell carcinomas. Genes Chromosom Cancer 1998;23: 67-71.
45. Vortmeyer AO, Merino MJ, Böni R, Liotta LA, Cavazzana A, Zhuang Z. Genetic changes associated with primary Merkel cell carcinoma. Am J Clin Pathol 1998;109:565-70.
46. Wingren S, van den Heuvel A, Gentile M, Olsen K, Hatschek T, Söderkvist P. Frequent allelic losses on chromosome 13q in human male breast carcinomas. Eur J Cancer 1997;33:2393-6.
47. Prechtel D, Werenskiöld AK, Prechtel K, Keller G, Hofler H. Frequent loss of heterozygosity at chromosome 13q12-13 with BRCA2 markers in sporadic male breast cancer. Diagn Mol Pathol 1998;7:57-62.
48. Scharnagel IM, Pack GT. Multiple basal cell ephiteliomas in a five year old child. Am J Dis Child 1949;77:647-51.
49. Golitz LE, Norris DA, Luekens CA Jr, Charles DM. Nevoid basal cell carcinoma syndrome: multiple basal cell carcinomas of the palm after radiation therapy. Arch Dermatol 1980;116: 1159-63.
50. Roth C, Breuninger H, Rassner G. Basalzellnaevus-Syndrom und Strahlentherapie. Akt Dermatol 1985;11:55-7.
51. Strong LC. Genetic and environmental interactions. Cancer 1977;40:1861-6.
52. Happle R. Genetik der Basaliome. In: Eichmann A, Schnyder UW, editors. Das Basaliom: der häufigste Tumor der Haut. Berlin: Springer; 1981. p. 17-28.
53. Happle R. Basaliom-Induktion [abstract]. Zentralbl Haut Geschlechtskr 1991;158:936.
54. Shanley SM, Dawkins H, Wainwright BJ, Wicking C, Heenan P, Eldon M, et al. Fine deletion mapping on the long arm of chromosome 9 in sporadic and familial basal cell carcinomas.Hum Mol Genet 1995;4:129-33.
55. Gorlin RJ. Nevoid basal cell carcinoma syndrome. Dermatol Clin 1995;13:113-25.
56. Levanat S, Gorlin RJ, Fallet S, Johnson DR, Fantasia JE, Bale AE.A two-hit model for developmental defects in Gorlin syndrome. Nature Genet 1996;12:85-7.
57. Gailani MR, Ståhle-Bäckdahl M, Leffell DJ, Glynn M, Zaphiropoulos PG, Pressman C, et al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nature Genet 1996;14:78-81.
58. Hahn H, Wicking C, Zaphiropoulos PG, Gailani MR, Shanley S, Chidambaram A, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996;85:841-51.
59. Johnson RL, Rothman AL, Xie JW, Goodrich LV, Bare JW, Bonifas JM, et al.Human homolog of patched,a candidate gene for the basal cell nevus syndrome. Science 1996;272:1668-71.
60. Nüsslein-Volhard C, Wieschaus E. Mutations affecting segment number and polarity in Drosophila.Nature 1980;287:795-801.
61. Nakano Y, Guerrero I, Hidalgo A, Taylor A, Whittle JRS, Ingham PW. A protein with several possible membrane-spanning domains encoded by the Drosophila segment polarity gene patched.Nature 1989;341:508-13.
62. Hooper JE, Scott MP. The Drosophila patched gene encodes a putative membrane protein required for segmental patterning. Cell 1989;59:751-65.
63. Sidransky D. Is human patched the gatekeeper of common skin cancers? Nature Genet 1996;14:7-8.
64. Shilo BZ. Dispatches from patched.Nature 1996;382:115-6.
65. Maesawa C, Tamura G, Iwaya T, Ogasawara S, Ishida K, Sato N, et al. Mutations in the human homologue of the Drosophila patched gene in esophageal squamous cell carcinoma.Genes Chromosom Cancer 1998;21:276-9.
66. Bale SJ, Falk RT, Rogers GR. Patching together the genetics of Gorlin syndrome. J Cutan Med Surg 1998;3:31-4.
67. Xin H, Matt D, Burg G, Böni R.Deletions at the human homolog of Drosophila patched gene on chromosome 9q22.3 in a subset of secaceous nevi [abstract]. Arch Dermatol Res 1999;291: 124.
68. Böni R, Matt D, Xin H, Nestle FO, Gilliet M, Burg G. High frequency of allelic deletion on 9p21 (p16 gene locus) in melanoma metastases of non-responders to peptide-pulsed dendritic cell vaccination [abstract]. Arch Dermatol Res 1999;403:124.
69. Clark WR Jr, Reimer RR, Greene M, Ainsworth AM, Mastrangelo MJ. Origin of familial malignant melanomas from heritable melanocytic lesions: ‘the B-K mole syndrome.’ Arch Dermatol 1978;114:732-8.
70. Greene MH, Clark WH Jr, Tucker MA, Elder DE, Kraemer KH, Guerry D IV, et al.Acquired precursors of cutaneous malignant melanoma: the familial dysplastic nevus syndrome. N Engl J Med 1985;312:91-7.
71. Happle R, Traupe H, Vakilzadeh F, Macher E. Arguments in favor of a polygenic inheritance of precursor nevi. J Am Acad Dermatol 1982;6:540-3.
72. Happle R. Dysplastic nevus ‘syndrome’: the emergence and decline of an erroneous concept. J Eur Acad Dermatol Venereol 1993;2:275-80.
73. Robinson WA, Norris D, Elefanty A, Markham N. Human acquired nevi are clonal [abstract]. J Invest Dermatol 1996; 106:883.
74. Böni R, Zhuang Z. Loss of heterozygosity detected on 1p and 9q in microdissected atypical nevi. Arch Dermatol 1998; 134:882.
75. Böni R, Vortmeyer AO, Stern JB, Burg G, Hofbauer G, Zhuang Z. Concordance of genetic changes in basal cell carcinoma and associated clusters of squamous cells. J Invest Dermatol 1998;111:173-4.
76. Waring AJ, Takata M, Rehman I, Rees JL. Loss of heterozygosity analysis of keratoacanthoma reveals multiple differences from cutaneous squamous cell carcinoma. Br J Cancer 1996;73:649-53.
77. Mao EJ, Schwartz SM, Daling JR, Beckmann AM. Loss of heterozygosity at 5q21-22 (adenomatous polyposis coli gene region) in oral squamous cell carcinoma is common and correlated with advanced disease. J Oral Pathol Med 1998;27:297- 302.
78. Wong YK, Liu TY, Chang KW, Lin SC, Chao TW, Li PL, et al. p53 alterations in betel quid- and tobacco-associated oral squamous cell carcinomas from Taiwan. J Oral Pathol Med 1998;27:243-8.
79. Scrable HJ, Witte DP, Lampkin BC, Cavenee WK. Chromosomal localization of the human rhabdomyosarcoma locus by mitotic recombination mapping.Nature 1987;329:645-7.
80. Carbonara C, Longa L, Grosso E, Borrone C, Garrè MG, Brisigotti M, et al. 9q34 loss of heterozygosity in a tuberous sclerosis astrocytoma suggests a growth suppressor-like activity also for the TSC1 gene. Hum Mol Genet 1994;3:1829-32.
81. Orellana C, Hernandez-Marti M, Martinez F, Castel V, Millan JM, Alvarez-Garijo JA, et al. Pediatric brain tumors: loss of heterozygosity at 17p and TP53 gene mutations. Cancer Genet Cytogenet 1998;102:93-9.
82. Ejeskar K, Aburatani H, Abrahamsson J, Kogner P, Martinsson T. Loss of heterozygosity of 3p markers in neuroblastoma tumours implicate a tumour-suppressor locus distal to the FHIT gene. Br J Cancer 1998;77:1787-91.
83. Karlbom AE, James CD, Boethius J, Cavenee WK, Collins VP, Nordenskjöld M, et al. Loss of heterozygosity in malignant gliomas involves at least three distinct regions on chromosome 10. Hum Genet 1993;92:169-74.
84. Zhu JJ, Santarius T, Wu X, Tsong J, Guha A, Wu JK, et al. Screening for loss of heterozygosity and microsatellite instability in oligodendrogliomas. Genes Chromosom Cancer 1998;21:207-16.
85. Chernova O, Cowell JK. Molecular definition of chromosome translocations involving 10q24 and 19q13 in human malignant glioma cells. Cancer Genet Cytogenet 1998;105:60-8.
86. Lee WC, Testa JR. Somatic genetic alterations in human malignant mesothelioma. Int J Oncol 1999;14:181-8.
87. Deguen B, Goutebroze L, Giovannini M, Boisson C, van der Neut R, Jaurand MC, et al. Heterogeneity of mesothelioma cell lines as defined by altered genomic structure and expression of the NF2 gene. Int J Cancer 1998;77:554-60.
88. Besnard-Guérin C, Newsham I, Winqvist R, Cavenee WK.A common region of loss of heterozygosity in Wilms’ tumor and embryonal rhabdomyosarcoma distal to the D11S988 locus on chromosome 11p15.5. Hum Genet 1996;97:163-70.
89. Grundy RG, Pritchard J, Scambler P, Cowell JK. Loss of heterozygosity on chromosome 16 in sporadic Wilms’ tumour. Br J Cancer 1998;78:1181-7.
90. Huff V. Wilms tumor genetics. Am J Med Genet 1998;79:260-7.
91. Rio PG, Pernin D, Bay JO, Albuisson E, Kwiatkowski F, De Latour M, et al. Loss of heterozygosity of BRCA1, BRCA2 and ATM genes in sporadic invasive ductal breast carcinoma.Int J Oncol 1998;13:849-53.
92. Lichy JH, Zavar M, Tsai MM, O’Leary TJ, Taubenberger JK. Loss of heterozygosity on chromosome 11p15 during histological progression in microdissected ductal carcinoma of the breast. Am J Pathol 1998;153:271-8.
93. Cleton-Jansen AM, Moerland EW, Kuipers-Dijkshoorn NJ, Callen DF, Sutherland GR, Hansen B, et al.At least two different regions are involved in allelic imbalance on chromosome arm 16q in breast cancer.Genes Chromosom Cancer 1994;9:101-7.
94. Wright K, Wilson PJ, Kerr J, Do K, Hurst T, Khoo SK, et al.Frequent loss of heterozygosity and three critical regions on the short arm of chromosome 8 in ovarian adenocarcinomas. Oncogene 1998;17:1185-8.
95. Suzuki M, Saito S, Saga Y, Ohwada M, Sato I. Loss of heterozygosity on chromosome 6q27 and p53 mutations in epithelial ovarian cancer.Med Oncol 1998;15:119-23.
96. Marsh DJ, Zheng Z, Zedenius J, Kremer H, Padberg GW, Larsson C, et al. Differential loss of heterozygosity in the region of the Cowden locus within 10q22-23 in follicular thyroid adenomas and carcinomas. Cancer Res 1997;57:500-3.
97. Uchino S, Noguchi S, Adachi M, Sato M, Yamashita H, Watanabe S, et al. Novel point mutations and allele loss at the RET locus in sporadic medullary thyroid carcinomas. Jpn J Cancer Res 1998;89:411-8.
98. Marchetti A, Pellegrini S, Sozzi G, Bertacca G, Gaeta P, Buttitta F, et al. Genetic analysis of lung tumours of non-smoking subjects: p53 gene mutations are constantly associated with loss of heterozygosity at the FHIT locus. Br J Cancer 1998;78:73-8.
99. Suzuki K, Ogura T, Yokose T, Nagai K, Mukai K, Kodama T, et al. Loss of heterozygosity in the tuberous sclerosis gene associated regions in adenocarcinoma of the lung accompanied by multiple atypical adenomatous hyperplasia. Int J Cancer 1998;79:384-9.
100. Endo C, Sagawa M, Sato M, Chen Y, Sakurada A, Aikawa H, et al. Sequential loss of heterozygosity in the progression of squamous cell carcinoma of the lung. Br J Cancer 1998;78:612-5.
101. Dong SM, Kim KM, Kim SY, Shin MS, Na EY, Lee SH, et al. Frequent somatic mutations in serine/threonine kinase 11/Peutz-Jeghers syndrome gene in left-sided colon cancer. Cancer Res 1998;58:3787-90.
102. Mueller JD, Haegle N, Keller G, Mueller E, Saretzky G, Bethke B, et al. Loss of heterozygosity and microsatellite instability in de novo versus ex-adenoma carcinomas of the colorectum. Am J Pathol 1998;153:1977-84.
103. Resta N, Simone C, Mareni C, Montera M, Gentile M, Susca F, et al. STK11 mutations in Peutz-Jeghers syndrome and sporadic colon cancer. Cancer Res 1998;58:4799-801.
104. El Sebai H, Ged C, Bonichon F, de Verneuil H, Longy M. Genetic alterations in colorectal cancer, comparative analysis of deletion events, and point mutations. Cancer Genet Cytogenet 1998;104:32-8.
105. Garcia-Patino E, Gomendio B, Lleonart M, Silva JM, Garcia JM, Provencio M, et al. Loss of heterozygosity in the region including the BRCA1 gene on 17q in colon cancer. Cancer Genet Cytogenet 1998;104:119-23.
106. Fang DC, Jass JR, Wang DX. Loss of heterozygosity and loss of expression of the DCC gene in gastric cancer. J Clin Pathol 1998;51:593-6.
107. Moskaluk CA, Rumpel CA. Allelic deletion in 11p15 is a common occurrence in esophageal and gastric adenocarcinoma. Cancer 1998;83:232-9.
108. Kimura M, Furukawa T, Abe T, Yatsuoka T, Youssef EM, Yokoyama T, et al. Identification of two common regions of allelic loss in chromosome arm 12q in human pancreatic cancer.Cancer Res 1998;58:2456-60.
109. Hoglund M, Gorunova L, Jonson T, Dawiskiba S, Andrén- Sandberg A, Stenman G, et al. Cytogenetic and FISH analyses of pancreatic carcinoma reveal breaks in 18q11 with consistent loss of 18q12-qter and frequent gain of 18p. Br J Cancer 1998;77:1893-9.
110. Shigyo M, Sugano K, Fukayama N, Taniguchi T, Tobisu K, Fujimoto H, et al. Allelic loss on chromosome 9 in bladder cancer tissues and urine samples detected by blunt-end singlestrand DNA conformation polymorphism. Int J Cancer 1998; 78:425-9.
111. Latil A, Cussenot O, Fournier G, Baron JC, Lidereau R. Loss of heterozygosity at 7q31 is a frequent and early event in prostate cancer. Clin Cancer Res 1995;1:1385-9.
112. Villuendas R, Sanchez-Beato M, Martinez JC, Saez AI, Martinez- Delgado B, Garcia JF, et al. Loss of p16/INK4A protein expression in non-Hodgkin’s lymphomas is a frequent finding associated with tumor progression. Am J Pathol 1998;153:887-97.
113. Mori N, Morosetti R, Spira S, Lee S, Ben-Yehuda D, Schiller G, et al. Chromosome band 1p36 contains a putative tumor suppressor gene important in the evolution of chronic myelocytic leukemia. Blood 1998;92:3405-9.
114. Giphart-Gassler M, De Nooij-Van Dalen A, van Buuren-van Seggelen V, Morolli B, Lohman P, Kluin-Nelemans H. A search for novel tumour suppressor genes for adult acute leukaemia by allelotyping at sub-telomeric chromosomal regions.Mutat Res 1998;400:409-19.
115. Legius E, Marchuk DA, Collins FS, Glover TW. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis.Nature Genet 1993;3:122-6.
116. Seizinger BR. NF1: A prevalent cause of tumorigenesis in human cancers? Nature Genet 1993;3:97-9.
117. Kai S, Sumita H, Fujioka K, Takahashi H, Hanzawa N, Funabiki T, et al. Loss of heterozygosity of NF1 gene in juvenile chronic myelogenous leukemia with neurofibromatosis type 1. Int J Hematol 1998;68:53-60.
118. Feinberg AP. Genomic imprinting and gene activation in cancer. Nature Genet 1993;4:110-3.
119. Kinzler KW, Vogelstein B. Familial cancer syndromes: the role of caretakers and gatekeepers. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. New York: McGraw- Hill; 1998. p. 241-2.
120. Fearon ER. Tumor suppressor genes. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. New York: McGraw-Hill; 1998. p. 229-36.
121. Shimokado K, Watanabe H, Sumii M, Miyagawa K, Kamiya K, Dohi K, et al. p53 gene mutation and loss of heterozygosity of chromosome 11 in methylcholanthrene-induced mouse sarcomas. Jpn J Cancer Res 1998;89:269-77.
122. Steenbergen RD, Hermsen MA, Walboomers JM, Meijer GA, Baak JP, Meijer CJ, et al. Non-random allelic losses at 3p, 11p, and 13q during HPV-mediated immortalization and concomitant loss of terminal differentiation of human keratinocytes. Int J Cancer 1998;76:412-7.
123. Sepp T, Yates JRW, Green AJ. Loss of heterozygosity in tuberous sclerosis hamartomas. J Med Genet 1996;33:962-4.
124. Pack S, Turner ML, Zhuang Z, Vortmeyer AO, Böni R, Skarulis M, et al. Cutaneous tumors in patients with multiple endrocrine neoplasia type 1 show allelic deletion of the MEN1 gene. J Invest Dermatol 1998;110:438-40.
125. Colman SD, Williams CA, Wallace MR. Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene.Nature Genet 1995;11:90-2.
126. Matt D, Xin H, Vortmeyer AO, Zhuang Z, Burg G, Böni R. Detection of loss of heterozygosity on chromosome 9q22.3 in microdissected sporadic trichoepithelioma [abstract]. Arch Dermatol Res 1999;403:124.
127. Verhoef S, Schrander-Stumpel CT, Vuzevski VD, Tempelaars A, Jansen LA, Malfeyt GA, et al. Familial cylindromatosis mimicking tuberous sclerosis complex and confirmation of the cylindromatosis locus, CYLD1, in a large family. J Med Genet 1998;35:841-5.
128. Irving RM, Moffat DA, Hardy DG, Barton DE, Xuereb JH, Maher ER. Somatic NF2 gene mutations in familial and non-familial vestibular schwannoma. Hum Mol Genet 1994;3:347-50.
129. Marsh DJ, Dahia PLM, Coulon V, Zheng Z, Dorion-Bonnet F, Call KM, et al. Allelic imbalance, including deletion of PTEN/MMACI, at the Cowden disease locus on 10q22-23 in hamartomas from patients with Cowden disease and germline PTEN mutations. Genes Chromosom Cancer 1998;21:61-9.
130. Radford DM, Ashley SM, Wells SA, Gerhard DS. Loss of heterozygosity of markers on chromosome 11 in tumors from patients with multiple endocrine neoplasia syndrome type 1. Cancer Res 1990;50:6529-33.
131. Morelli A, Falchetti A, Amorosi A, Tonelli F, Bearzi I, Ranaldi R, et al. Clonal analysis by chromosome 11 microsatellite-PCR of microdissected parathyroid tumors from MEN1 patients. Biochem Biophys Res Comm 1996;227:736-42.
132. Lubensky IA, Debelenko LV, Zhuang Z, Emmert-Buck MR, Dong Q, Chandrasekharappa SC, et al. Allelic deletions in chromosome 11q13 in multiple tumors from individual MEN1 patients. Cancer Res 1996;56:5272-8.
133. Stemmer-Rachamimov AO, Ino Y, Lim ZY, Jacoby LB, MacCollin M, Gusella JF, et al. Loss of the NF2 gene and merlin occur by the tumorlet stage of schwannoma development in neurofibromatosis 2. J Neuropathol Exp Neurol 1998;57:1164-7.
134. Bartsch D, Kopp I, Bergenfelz A, Rieder H, Munch K, Jager K, et al. MEN1 gene mutations in 12 MEN1 families and their associated tumors. Eur J Endocrinol 1998;139:416-20.
135. Spirio LN, Samowitz W, Robertson J, Robertson M, Burt RW, Leppert M, et al. Alleles of APC modulate the frequency and classes of mutations that lead to colon polyps. Nature Genet 1998;20:385-8.
136. Valdes N, Alvarez V, Diaz-Cadorniga F, Aller J, Villazon F, Garcia I, et al. Multiple endrocrine neoplasia type 1 (MEN1): LOH studies in an affected family and in sporadic cases. Anticancer Res 1998;18:2685-9.
137. Carling T, Correa P, Hessman O, Hedberg J, Skogseid B, Lindberg D, et al. Parathyroid MEN1 gene mutations in relation to clinical characteristics of nonfamilial primary hyperparathyroidism. Clin Endocrinol Metab 1998;83:2960-3.
138. Marx S, Spiegel AM, Skarulis MC, Doppman JL, Collins FS, Liotta LA. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med 1998;129:484-94.
139. Weil RJ, Vortmeyer AO, Huang S, Böni R, Lubensky IA, Pack S, et al. 11q13 allelic loss in pituitary tumors in patients with multiple endocrine neoplasia syndrome type 1. Clin Cancer Res 1998;4:1673-8.
140. Gruber SB, Entius MM, Petersen GM, Laken SJ, Longo PA, Boyer R, et al. Pathogenesis of adenocarcinoma in Peutz-Jeghers syndrome. Cancer Res 1998;58:5267-70.
141. Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, Jeschke R, et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase.Nature Genet 1998;18:38-42.
142. Green AJ, Johnson PH, Yates JRW. Loss of heterozygosity on chromosome 16p13.3 in hamartomas from tuberous sclerosis patients.Nature Genet 1994;6:193-6.
143. Henske EP, Scheithauer BW, Short MP, Wollmann R, Nahmias J, Hornigold N, et al. Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am J Hum Genet 1996;59:400-6.
144. Green AJ, Smith M, Yates JRW. The tuberous sclerosis gene on chromosome 9q34 acts as a growth suppressor. Hum Mol Genet 1994;3:1833-1834.
145. Comings DE. Review of Gomez MR. Tuberous sclerosis [book review]. Am J Hum Genet 1980;32:285-6.
146. Smolarek TA, Wessner LL, McCormack FX, Mylet JC, Menon AG, Henske EP. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet 1998;62:810-5.
147. Böni R, Matt D, Burg G, Tronnier M, Vortmeyer A, Zhuang Z. Ultraviolet-induced acute histological changes in irradiated nevi are not associated with allelic loss. Arch Dermatol 1998;134:853-6.
148. Happle R. Segmental forms of autosomal dominant skin disorders: different types of severity reflect different states of zygosity. Am J Med Genet 1996;66:241-242.
149. Happle R. A rule concerning the segmental manifestation of autosomal dominant skin disorders: review of clinical examples providing evidence for dichotomous types of severity. Arch Dermatol 1997;133:1505-9.
150. Chester BJ, Brown L. Darier’s disease resembling linear verrucous epidermal nevus. Arch Dermatol 1959;80:625-6.
151. Esche C, Pier A, Zumdick M, Krutmann J, Ruzicka T. Morbus Darier im Verlauf der Blaschko-Linien. Z Hautkr 1995;70:758- 60.
152. Happle R, Itin PH, Brun AM. Type 2 segmental Darier disease: a report of two cases. Eur J Dermatol In press.
153. Hadlich J, Linse R. Keratosen mit granulärer Degeneration und ihre Beziehungen zueinander. II.Mitteilung: Heterophänie von epidermolytic hyperkeratosis (Erythrodermia congenitalis ichthyosiformis bullosa), Naevus verrucosus hystricoides und Keratosis palmoplantaris cum degeneratione granulosa Vörner.Dermatol Monatsschr 1989;175:418-24.
154. Eng AM, Brody P, Rhee HL, Bronson DM. Congenital ichthyosiform erythroderma and epidermal nevus. Int J Dermatol 1991;30:284-7.
155. Vakilzadeh F, Kolde G. Relapsing linear acantholytic dermatosis. Br J Dermatol 1985;112:349-55.
156. Restano I, Cambiaghi S, Brusasco A, Tadini G, Caputo R.A hyperkeratotic linear lesion in a girl with KID syndrome: A further example of early allelic loss? Eur J Dermatol 1999;9:142-3.
157. Gandola M. La porocheratosi di Mibelli: aspetti evolutivi tardivi e associazioni morbose insolite. Boll Soc Medicochir 1951;51:273-92.
158. Ehlers G, Rothe A. Porokeratosis Mibelli mit multiplen Praecancerosen und Plattenepithelcarcinomen. Hautarzt 1971;22:68-73.
159. Welton WA. Linear porokeratosis in a family with DSAP. Arch Dermatol 1972;106:263.
160. Moreland ME, Wyre HW.Porokeratosis:two morphologic forms within a family. Arch Dermatol 1981;117:245-6.
161. Machino H, Miki Y, Teramoto T, Shiraishi S, Sasaki MS. Cytogenetic studies in a patient with porokeratosis of Mibelli, multiple cancers and a forme fruste of Werner’s syndrome. Br J Dermatol 1984;111:579-86.
162. Dover JS, Phillips TJ, Burns DA, Krafchik BR. Disseminated superficial actinic porokeratosis: coexistence with other porokeratotic variants. Arch Dermatol 1986;122:887-9.
163. Commens CA, Shumack SP. Linear porokeratosis in two families with disseminated superficial actinic porokeratosis. Pediatr Dermatol 1987;4:209-14.
164. Feldman SR, Crosby DL, Tomsick RS. Scaly atrophic lesions both scattered and in linear arrays. Diagnosis: disseminated superficial actinic porokeratosis in a patient with linear porokeratosis. Arch Dermatol 1991;127:1219, 1222.
165. Morton CA, Shuttleworth D, Douglas WS. Porokeratosis and Crohn’s disease. J Am Acad Dermatol 1995;32:894-7.
166. Freyschmidt-Paul P, Hoffmann R, König A, Happle R. Linear porokeratosis superimposed on disseminated superficial actinic porokeratosis: report of two cases exemplifying the concept of type 2 segmental manifestation of autosomal dominant skin disorders. J Am Acad Dermatol In press.
167. Happle R. Somatic recombination may explain linear porokeratosis associated with disseminated superficial actinic porokeratosis. Am J Med Genet 1991;39:237.
168. Happle R. Cancer proneness of linear porokeratosis may be explained by allelic loss.Dermatology 1997;195:20-5.
169. Archer CB, Glover M, Atherton DJ. Segmental neurofibromatosis with generalized café au lait spots. Br J Dermatol 1988;119 (suppl 33):96-7.
170. Wosyka H. Leiomyoblastoma cutis multiplex in segmentärer Anordnung.Dermatol Wochenschr 1934;99:1110-2.
171. Rudner EJ, Schwartz OD, Grekin JN. Multiple cutaneous leiomyoma in identical twins. Arch Dermatol 1964;90:81-2.
172. Mezzadra G. Leiomioma cutaneo multiplo ereditario: studio di un caso sistematizzato in soggetto maschile appartenente a famiglia portatrice di leiomiomatosi cutanea e fibromiomatosi uterina.Minerva Dermatol 1965;40:388-93.
173. Berendes U, Kühner A, Schnyder UW. Segmentary and disseminated lesions in multiple hereditary cutaneous leiomyoma. Humangenetik 1971;13:81-2.
174. Corbett R. Multiple leiomyomata. Br J Dermatol 1984;26:70-1.
175. Camacho F, Jorquera E, Vasquez FJ, Hevia A. Giant zoniform leiomyoma: light and electron microscopy study. Eur J Dermatol 1994;4:384-6.
176. Wilms NA, Douglass MC. An unusual case of preponderantly right-sided syringomas. Arch Dermatol 1981;117:308.
177. Kikuchi I, Idemori M, Okazaki M. Plaque type syringoma. J Dermatol 1979;6:329-31.
178. Geffner RE, Goslen JB, Santa Cruz DJ. Linear and dermatomal trichoepitheliomas. J Am Acad Dermatol 1986;14:927-30.
179. Naversen DN, Worland RG, Burket JM. Giant glomangioma. J Am Acad Dermatol 1986;14:1083-4.
180. Tomasini C, Aloi F, Castelli F.Tumore glomico multiplo: varietà a placca. G Ital Dermatol Venereol 1991;126:103-6.
181. Berger H, Hundeiker M. Multiple Glomustumoren als Phakomatose.Dermatol Wochenschr 1967;153:673-8.
182. Landthaler M, Braun-Falco O, Eckert F, Stolz W, Dorn M, Wolff HH. Congenital multiple plaquelike glomus tumors. Arch Dermatol 1990;126:1203-7.
183. Hamlet KR, Ellis CN, Baltzer R. Diffuse and progressive nodular plaques. Diagnosis: glomangiomas. Arch Dermatol 1998;134: 863-6.
184. Baselga E, Drolet BA, van Tuinen P, Esterly NB, Happle R. Dyskeratosis congenita with linear areas of severe cutaneous involvement. Am J Med Genet 1998;75:492-6.
185. Trembath RC, Clough RL, Rosbotham JL, Jones AB, Camp RD, Frodsham A, et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 1997;6:813-20.
186. Beek CH, Jantzen J. On acute linear dermatoses. Acta Derm Venereol (Stockh) 1955;35:319-26.
187. Leslie G. Linear psoriasis. Br J Dermatol 1951;63:262-3.
188. Happle R. Somatic recombination may explain linear psoriasis. J Med Genet 1991;28:337.
189. Zachos G, Koumantaki E, Vareltzidis A, Spandidos DA. Evidence for loss of heterozygosity in human psoriatic lesions. Br J Dermatol 1998;139:974-7.
190. Kanoh H, Ichihashi N, Kamiya H, Seishima M, Akiyama T, Ichiki Y, et al. Linear pustular psoriasis that developed in a patient with generalized pustular psoriasis. J Am Acad Dermatol 1998;39:635-7.
191. Taïeb A. Linear atopic dermatitis (‘naevus atopicus’): A pathogenetic clue? Br J Dermatol 1994;131:134-5.
192. Madden JF. Zosteriform lichen planus. Arch Dermatol Syph 1940;41:620.
193. Nagy G, Szabó E, Herpai S. Lichen zosteriformis. Z Haut Geschlechtskr 1968;43:509-14.
194. Davis MI. Zosteriform lichen planus. Arch Dermatol Syph 1938;38:615-8.
195. Irgang S. Zosteriform lichen planus: case report. Cutis 1968;4:1076-8.
196. Fink-Puches R, Hofmann-Wellenhof R, Smolle J. Zosteriform lichen planus.Dermatology 1996;192:375-7.
197. Wilson BB, Lockman DW. Linear lichenoid graft-vs-host disease. Arch Dermatol 1994;130:1206-7.
198. Lee MS, Atkinson K, Kossard S. Lichenoid graft-versus-host disease occurring in Blaschko’s lines. Eur J Dermatol 1996;6:282- 3.
199. Baselga E, Drolet BA, Segura AD, Leonardi CL, Esterly NB. Dermatomal lichenoid chronic graft-vs-host disease following varicella-zoster infection despite absence of viral genome. J Cutan Pathol 1996;23:576-81.
200. Freemer CS, Farmer ER, Corio RL, Altomonte VL, Wagner JE, Vogelsang GB, et al. Lichenoid chronic graft-vs-host disease occurring in a dermatomal distribution. Arch Dermatol 1994;130:70-2.
201. Roholt NS, Lapière JC, Wang JI, Bernstein LJ, Woodley DT, Eramo LR. Localized linear bullous eruption of systemic lupus erythematosus in a child. Pediatr Dermatol 1995;12:138-44.
202. Crovato F, Desirello G, Nazzari G, De Marchi R. Linear pemphigus vulgaris after X-ray irradiation. Dermatology 1989;179: 135-6.
203. Turner RJ, Dahl MGC, Shuster S, Rees JL. Mosaic atopic eczema cured by autotransplantation? Lancet 1998;352:961.
204. Saxena AK, Nigam PK. Unilateral lichen planus. Cutis 1988; 42:142.
205. Long CC, Finlay AY.Multiple linear lichen planus in the lines of Blaschko. Br J Dermatol 1996;135:275-6.
206. Kikuchi A, Okamoto S, Takahashi S, Asano S, Nishikawa T. Linear chronic cutaneous graft-versus-host disease. J Am Acad Dermatol 1997;37:1004-6.
207. Sigal-Nahum M, Konqui A, Gaulier A, Sigal S. Linear fixed drug eruption. Br J Dermatol 1988;118:849-58.
208. Özkaya-Bayazit E, Baykal C. Trimethoprim-induced linear fixed drug eruption. Br J Dermatol 1997;137:1028-9.
209. Megahed M, Reinauer S, Scharffetter-Kochanek K, Milde P, Hölzle E, Goerz G, et al. Acquired relapsing self-healing Blaschko dermatitis. J Am Acad Dermatol 1994;31:849-52.
210. Heid E, Grosshans E, Gonda J, Paré M, Lipsker D. Éruption blaschko-linéaire avec biologie lupique. Ann Dermatol Venereol 1996;123:331-3.
211. Richarz U, Hübner J, Schmeel A, Bauer R. Striärer Lupus erythe- matodes im Verlauf der Blaschko-Linien. Hautarzt 1986;37: 335-7.
212. Innocenzi D, Pranteda G, Giombini S, Silipo V, Bottoni U, Calvieri S. Linear lupus erythematosus profundus in an adolescent.Eur J Dermatol 1997;7:445-7.
213. Beers B, Kalish RS, Kaye VN, Dahl MV.Unilateral linear lichenoid eruption after bone marrow transplantation:An unmasking of tolerance to an abnormal keratinocyte clone? J Am Acad Dermatol 1993;28:888-92.
214. Whitehouse HLK. Genetic recombination: understanding the mechanisms. Chichester:Wiley; 1982. p. 214-24.
215. Graf U, Würgler FE, Katz AJ, Frei H, Juon H, Hall CB, et al. Somatic mutation and recombination test in Drosophila melanogaster. Environ Mutagen 1984;6:153-88.
216. Graf U. Analysis of the relationship between age of larvae at mutagen treatment and frequency and size of spots in the wing somatic mutation and recombination test in Drosophila melanogaster. Experientia 1995;51:168-73.
217. Graf U, Frei H, Kägi A, Katz AJ, Würgler FE. Thirty compounds tested in the Drosophila wing spot test. Mutat Res 1989; 222:359-73.
218. Graf U, Abraham SK, Guzman-Rincon J, Würgler FE. Antigenotoxicity studies in Drosophila melanogaster. Mutat Res 1998; 402:203-9.
219. Harrison BJ, Carpenter R. Somatic crossing-over in Antirrhinum majus.Heredity 1977;38:169-89.
220. Vig BK. Somatic crossing over in Glycine max (L) Merrill: effect of some inhibitors of DNA synthesis on the induction of somatic crossing over and point mutations. Genetics 1973; 73:583-96.
221. Happle R, Koopman R, Mier PD.Hypothesis: vascular twin naevi and somatic recombination in man. Lancet 1990;335:376-8.
222. Happle R. Allelic somatic mutations may explain vascular twin nevi. Hum Genet 1991;86:321-2.
223. Happle R, Barbi G, Eckert D, Kennerknecht I. “Cutis tricolor”: congenital hyper- and hypopigmented macules associated with a sporadic multisystem birth defect: An unusual example of twin spotting? J Med Genet 1997;8:676-8.
224. De las Heras E, Boixeda JP, Leder A, Happle R. Paired melanotic and achromic macules in a case of phacomatosis pigmentovascularis: A further example of twin spotting? Am J Med Genet 1997;70:336-7.
225. Clark RD, Donnai D, Rogers J, Cooper J, Baraitser M.Proteus syndrome: an expanded phenotype.Am J Med Genet 1987;27:99- 117.
226. Wiedemann HR, Burgio GR, Aldenhoff P, Kunze J, Kaufmann HJ, Schirg E. The Proteus syndrome: partial gigantism of the hands and/or feet, nevi, hemihypertrophy, subcutaneous tumors, macrocephaly or other skull anomalies and possible accelerated growth and visceral affections. Eur J Pediatr 1983;140:5-12.
227. Costa T, Fitch N, Azouz EM. Proteus syndrome: report of two cases with pelvic lipomatosis. Pediatrics 1985;76:985-9.
228. McCall S, Ramzy MI, Curé JK, Pai GS. Encephalocraniocutaneous lipomatosis and the Proteus syndrome: distinct entities with overlapping manifestations. Am J Med Genet 1992;43: 662-8.
229. Havard S, Enjolras O, Lessana-Leibowitch M, Escande JP. Syndrome Protée: huit cas. Ann Dermatol Venereol 1994; 121:303-8.
230. Happle R. Lipomatosis and partial lipohypoplasia in Proteus syndrome: A clinical clue for twin spotting? Am J Med Genet 1995;56:332-3.
231. Happle R. Elattoproteus syndrome: delineation of an inverse form of Proteus syndrome. Am J Med Genet 1999;84:25-8.
232. Happle R, Steijlen PM, Theile U, Karitzky D, Tinschert S, Albrecht-Nebe H, et al. Patchy dermal hypoplasia as a charac-teristic feature of Proteus syndrome. Arch Dermatol 1997; 133:77-80.
233. Happle R, König A. Dominant traits may give rise to paired patches of either excessive or absent involvement. Am J Med Genet 1999;84:176-8.
234. Hasegawa Y, Yasuhara M. Phakomatosis pigmentovascularis type IVa. Arch Dermatol 1985;121:651-5.
235. Happle R, Steijlen PM. Phacomatosis pigmentovascularis gedeutet als ein Phänomen der Zwillingsflecken. Hautarzt 1989;40:721-4.
236. Happle R, Hoffmann R, Restano L, Caputo R, Tadini G. Phacomatosis pigmentokeratotica: a melanocytic-epidermal twin nevus syndrome. Am J Med Genet 1996;65:363-5.
237. Hermes B, Cremer B, Happle R, Henz BM. Phacomatosis pigmentokeratotica: a patient with the rare melanocytic-epidermal twin nevus syndrome.Dermatology 1997;194:77-9.
238. Tadini G, Restano L, Gonzáles-Pérez R, Gonzáles-Enseñat A, Vincente-Villa MA, Cambiaghi S, et al. Phacomatosis pigmentokeratotica: report of new cases and further delineation of the syndrome. Arch Dermatol 1998;134:333-7.
239. Wagner RF, Grande DJ, Bhawan J, Hellerstein MK, Longcope C. Unilateral dermatomal superficial telangiectasia overlapping Becker’s melanosis. Int J Dermatol 1989;28:595-6.
240. Menni S, Grimalt R, Caputo R. Unilateral eruptive psoriasis and lichen striatus. Pediatr Dermatol 1991;8:322-4.
241. Happle R. Paradominant inheritance: a possible explanation for Becker’s pigmented hairy nevus. Eur J Dermatol 1992;2:39-40.
242. Happle R. Klippel-Trenaunay syndrome: Is it a paradominant trait? Br J Dermatol 1993;128:465.
243. Happle R, König A. Familial naevus sebaceus may be explained by paradominant transmission. Br J Dermatol In press.
244. Del Rio E. Nevo de Becker: ¿Una dermatosis nevoide hereditaria? Actas Dermosifiliogr 1997;88:567-73.
245. Book SE, Glass AT, Laude TA. Congenital Becker’s nevus with a familial association. Pediatr Dermatol 1997;14:373-5.
246. Happle R, Koopman RJJ. Becker nevus syndrome. Am J Med Genet 1997;68:357-61.
247. Benedetto L, Blumenthal N, Madjar D, Sturman S, Hashimoto K. Familial nevus sebaceus. J Am Acad Dermatol 1990;23:130-2.
248. Sahl WJ. Familial nevus sebaceus of Jadassohn: occurrence in three generations. J Am Acad Dermatol 1990;22:853-4.
249. Fearfield LA, Bunker CD. Familial naevus sebaceus of Jadassohn. Br J Dermatol 1998;139:1119-20.
250. Monk BE, Vollum DI. Familial naevus sebaceus. J R Soc Med 1982;75:660-1.
251. Crosti C, Betti R. Inherited extensive speckled lentiginous nevus with ichthyosis: report of a previously undescribed association. Arch Dermatol 1994;130:393-5.
252. Debicka A, Adamczak P. Przypadek dziedziczenia zespo/lu Sturge’a-Webera [A case of hereditary Sturge-Weber syndrome]. Klin Oczna 1979;81:541-2.
253. Alvoet GE, Jorens PG, Roelen LM. Genetic aspects of the Klippel-Trenaunay syndrome. Br J Dermatol 1992;126:603-7.
254. Ceballos-Quintal JM, Pinto-Escalante D, Castillo-Zapata I.A new case of Klippel-Trenaunay-Weber (KTW) syndrome: evidence of autosomal dominant inheritance. Am J Med Genet 1996;63:426-7.
255. Cardoso H, Vignale R, Abreu de Sastre H. Familial naevus anaemicus [abstract]. Am J Hum Genet 1975;27:24A.
256. Wilkin JK, Smith JG Jr, Cullison DA, Peters GE, Rodriquez-Rigau LJ, Feucht CL. Unilateral dermatomal superficial telangiectasia: nine new cases and a review of unilateral dermatomal superficial telangiectasia. J Am Acad Dermatol 1983;8:468-77.
257. Jonkman MF, Scheffer H, Stulp R, Pas HH, Nijenhuis M, Heeres K, et al. Revertant mosaicism in epidermolysis bullosa caused by mitotic gene conversion. Cell 1997;88:543-51.
258. Ellis NA, Lennon DJ, Proytcheva M, Alhadeff B, Henderson EE, German J. Somatic intragenic recombination within the mutated locus BLM can correct the high sister-chromatid exchange phenotype of Bloom syndrome cells. Am J Hum Genet 1995;57:1019-27.
259. Weksberg R.Low-sister-chromatid-exchange Bloom syndrome cell lines: an important new tool for mapping the basic genetic defect in Bloom syndrome and for unraveling the biology of human tumor development. Am J Hum Genet 1995;75:994-7.
260. Newton MA, Gould MN, Reznikoff CA, Haag JD. On the statistical analysis of allelic-loss data. Stat Med 1998;17:1425-45.
261. Den Otter W, Koten JW, van der Vegt BJH, Beemer FA, Boxma OJ, de Graaf PW, et al. Hereditary cancer and its clinical implications: a view. Anticancer Res 1990;10:489-96.
262. Der Kinderen DJ, Boxma OJ, Koten JW, Den Otter W. Stochastic theory of oncogenesis. Anticancer Res 1990;10:497-504.
263. Chao LY, Huff V, Tomlinson G, Riccardi VM, Strong LC, Saunders GF. Genetic mosaicism in normal tissues of Wilms’ tumour patients.Nature Genet 1993;3:127-31.
264. McDonald JM, Douglass EC, Fisher R, Geiser CF, Krill CE, Strong LC, et al. Linkage of familial Wilms’ tumor predisposition to chromosome 19 and a two-locus model for the etiology of familial tumors. Cancer Res 1998;58:1387-90.
265. Dolan K, Garde J, Gosney J, Sissons M, Wright T, Kingsnorth AN, et al. Allelotype analysis of oesophageal adenocarcinoma: loss of heterozygosity occurs at multiple sites. Br J Cancer 1998; 78:950-7.